"Omics" analyses of data from the IPF-PRO Registry

Please find below a podcast of Dr Jamie Todd discussing how data from the IPF-PRO Registry are being used to investigate circulating biomarkers of disease severity and progression in patients with IPF.

microphone
 

Ruan P et al. Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respir Res 2023;24(1):141.

Header - Navigation Icon

The IPF-PRO/ILD-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI) and run in collaboration with the Duke Clinical Research Institute (DCRI) and enrolling centers. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment for development of this podcast or the article on which it is based. Editorial support on the article and podcast was provided by Fleishman-Hillard, London, UK, which was contracted and funded by BIPI. Boehringer Ingelheim (BI) was given the opportunity to review the article and podcast for medical and scientific accuracy as well as intellectual property considerations.